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Abstract
Background: While point of care testing (PoCT) for general practitioners is becoming increasingly popular, few studies 
have investigated whether it represents value for money. This study aims to assess the relative cost-effectiveness of 
PoCT in general practice (GP) compared to usual testing practice through a pathology laboratory.
Methods: A cost-effectiveness analysis based on a randomized controlled trial with 4,968 patients followed up for 18 
months and fifty-three general practices in urban, rural and remote locations across three states in Australia.
The incremental costs and health outcomes associated with a clinical strategy of PoCT for INR, HbA1c, lipids, and ACR 
were compared to those from pathology laboratory testing. Costs were expressed in year 2006 Australian dollars. Non-
parametric bootstrapping was used to generate 95% confidence intervals.
Results: The point estimate of the total direct costs per patient to the health care sector for PoCT was less for ACR than 
for pathology laboratory testing, but greater for INR, HbA1c and Lipids, although none of these differences was 
statistically significant. PoCT led to significant cost savings to patients and their families. When uncertainty around the 
point estimates was taken into account, the incremental cost-effectiveness ratio (ICER) for PoCT was found to be 
unfavourable for INR, but somewhat favourable for ACR, while substantial uncertainty still surrounds PoCT for HbA1c 
and Lipids.
Conclusions: The decision whether to fund PoCT will depend on the price society is willing to pay for achievement of 
the non-standard intermediate outcome indicator.
Trial registration: Australian New Zealand Clinical Trial Registry ACTRN12605000272695
Background
While a number of studies have been undertaken on
PoCT in a primary care setting, few of these have
included an economic analysis. [1] Hobbs et al [2], in a
systematic review of PoCT in primary care, were unable
to draw a conclusion on its cost-effectiveness because of
insufficient data. More recently, the National Academy of
Clinical Biochemistry's systematic review of PoCT [3]
and an updated systematic review of PoCT in GP [4] have
confirmed the paucity of reliable evidence on the cost-
effectiveness of PoCT. Some studies indicate that PoCT is
more expensive when compared to laboratory testing [5],
but it has been argued that the costs of rapid availability
of results may be justified by long term societal gains
such as prolonged life or by reduced hospital stays [1].
However, it should be noted that the cost-effectiveness of
PoCT is likely to vary according to the disease and the
test in question [5]. Since the overall resources available
to the health system are inevitably limited, it is important
to ensure that the resources allocated to these tests are
optimised.
The cost-effectiveness analysis was conducted along-
side the Point of Care Testing in General Practice Trial, a
randomised control trial in Australia [6]. Four tests were
assessed in the Trial - internationalised normalised ratio
(INR) of the prothrombin time, glycated hemoglobin
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(HbA1c), lipids (total cholesterol, triglycerides and HDL-
C) and urine albumin creatinine ratio (ACR). The aim of
the present analysis was to assess the incremental cost-
effectiveness of a clinical strategy based on performing
P o C T  i n  G P  c o m p a r e d  t o  c u r r e n t  p r a c t i c e  o f  t e s t i n g
through a pathology laboratory. The perspective was that
of Australian society overall.
Methods
PoCT Trial
This study was part of the Point of Care Testing in Gen-
eral Practice Trial which was conducted in 2005-2007. It
was an Australian Government funded multi-centre,
cluster randomised controlled trial to determine the
safety and clinical effectiveness of PoCT in general prac-
tice and stakeholder satisfaction with its use [6]. Briefly,
practices were recruited from three geographic locations
(urban, rural and remote) and from these practices
patients were recruited with diabetes, hyperlipidaemia
and/or being on anticoagulant therapy. A total of 4968
patients were recruited, with 3010 and 1958 patients in
the intervention and control groups respectively. Patients
in the intervention group had their samples taken in the
practice, with pathology testing being performed using
three PoCT devices located there. Patients in the control
group had their samples taken either in the practice and
forwarded to the local laboratories for pathology testing
or at the local laboratory or collection centre. For both
groups, there was no patient copayment for the pathology
testing. The Trial has been described elsewhere, provid-
ing in detail the methodology, rationale, recruitment pro-
cess and baseline patient characteristics. The latter are
provided in Table 1[6]. Ethical approval was obtained
from five independent Australian Human Research Ethics
Committees.
Resource use and Unit costs
Resource use data were collected prospectively during
the Trial. The costs of the PoCT strategy were calculated
by quantifying the resources used and assigning to them
the relevant unit cost. Initial costs, induced costs and
averted costs were considered. Fees and charges were
used as proxies for opportunity costs. The actual point of
care test costs were based on the Medicare Australia fees
established for the Trial. The sources of unit cost and vol-
ume data for each type of test are outlined in Table 2. The
cost analysis was undertaken using 18 months of T rial
data. Costs were expressed in calendar year 2006 Austra-
lian dollars, adjusted where necessary by the Consumer
Price Index (CPI) [7]. For comparison, over that year, one
Australian dollar was worth 0.453 English pounds (based
on purchasing power parities) [8].
Health outcome indicator
The intermediate outcome indicator used in the cost-
effectiveness analysis was the proportion of patients
within the therapeutic range for each condition at the end
of the Trial [6,9]. The point estimates and confidence
intervals for the health outcome indicators are presented
in Bubner et al [9]. The short time horizon of the trial
mitigated against using survival as an outcome indicator.
Statistical analyses
In general, the strategy was to calculate the overall incre-
ment in cost for all practices and participants over the
Trial period. Multiple imputation was used to address
missing data issues.
Table 1: Summary characteristics of patients
Characteristics Freq (%) Intervention (n = 3010) Control (n = 1958) Total (n = 4968)
Sex Male 1630 (54.2) 1018 (52.0) 2648 (53.3)
Age group (years) 18-39 52 (1.7) 21 (1.1) 73 (1.5)
40-49 199 (9.6) 109 (5.6) 308 (6.2)
50-59 573 (19.0) 335 (17.1) 908 (18.3)
60-69 1015 (33.7) 604 (30.8) 1619 (32.6)
70-79 867 (28.8) 680 (34.7) 1547 (31.1)
80+ 304 (10.1) 209 (10.7) 513 (10.3)
Age (years) median (IQ range) 66.0 (59.0-74.0) 68.0 (60.0-75.0) 67.0 (59.0-75.0)
Geographic region Urban 897 (29.8) 840 (42.9) 1737 (35.0)
Rural 917 (30.5) 447 (22.8) 1364 (27.5)
Remote 1196 (39.7) 671 (34.3) 1867 (37.6)
Condition* Anticoagulant therapy 572 (19.0) 372 (19.0) 944 (19.0)
Diabetes 1182 (39.3) 785 (40.1) 1967 (39.6)
Hyperlipidaemia 2356 (78.3) 1463 (74.7) 3819 (76.9)
*Patients could have more than one conditionLaurence et al. BMC Health Services Research 2010, 10:165
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Table 2: Resource use items and unit costs for all tests
Category of resource Description Source Volume Unit Cost
Establishment 
Program
PoCT equipment Industry sources Equivalent annual cost 
over clinically useful 
life (3 years)
Device Training initial 
and refresher
Trial Twice - at 
commencement of 
Trial and 12 months 
later
Accreditation Trial Annual
Pathology testing Pathology tests - PoCT 
and laboratory 
testing*
Medicare Australia 
data
No. of tests claimed 100% of MBS fee for 
PoCT.
85% of schedule fee for 
laboratory test**
Consultations - 
including where PoCT 
test ordered
Medicare Australia 
data
No. of consultations Actual charge
Copayments*** Medicare Australia 
data
No. of consultations Actual charge minus 
MBS fee rebate
Device Operator time 
(test, notes etc)
Time and motion study 
of sample of practices
No. of tests claimed SA Nurses Award - 
Registered Nurse 3rd 
year + oncosts
Patient follow-up of 
test results (GP and 
nurse)
Time and motion study No. of tests claimed SA Nurses Award - 
Registered Nurse 3rd 
year + oncosts
SADI Division GP 
claims policy 
2005-2007
Patient Episode 
Initiation
Medicare Australia 
data
No.r of episodes 
claimed
85% of schedule fee**
Quality management Quality Assurance 
Program
Industry source Annual
Quality control Device Group No. of QC tests 
(monthly)
Quality assurance RCPA QAP Pty Ltd No. of QA tests 
(monthly
Device Operator time 
for QA and QC
Time and motion study Number of QA and QC 
tests
SA Nurses Award - 
Registered Nurse 3rd 
year + oncosts
Consumables and 
maintenance
Consumables - per test 
items and periodically 
used items****
Industry sources Per test cost
Annual maintenance 
fee
Nil. Manufacturers 
replaced defective 
devices at no cost.
Downstream costs Hospital admissions 
(related only to disease 
group in study)
Case note audit on 
sample of patients
No. of visits National Hospital Data 
Collection - Public 
Section Estimated 
Round 9 (2004-05) - 
AR-DRG 5.0*****Laurence et al. BMC Health Services Research 2010, 10:165
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Generalised Estimating Equations (GEE) were used to
estimate the predicted number of healthcare item usages
for a participant in the intervention and control arms,
controlling for gender, age and correlation at the practice
level. Estimates were adjusted for the length of time
involved in the Trial. A Poisson model with log link was
used to analyse count data; continuous data were
assumed to be normally distributed.
From the original sample, 500 bootstrap samples were
obtained, sampling at the practice level. This resulted in
each bootstrap sample having different numbers of sub-
jects (due to different numbers of subjects attending each
practice), but over all bootstrap samples, the correlation
due to clustering at the practice level was controlled. The
2.5th and 97.5th percentile values of the distribution
obtained from bootstrapping the GEE estimates were
taken as the limits of the 95% confidence intervals (CIs).
CIs were obtained for unit costs and mean costs and dif-
ferences.
All imputations and analyses were performed with SAS
9.1 (Cary, NC, USA).
Sensitivity analysis
To examine the influence of uncertainty in the variables,
one-way sensitivity analyses were undertaken on each
resource item for which the underlying variable had a dis-
tribution. The upper and lower limits of the CIs were
used as the ranges for the sensitivity analyses, which were
only conducted on the health service costs, as the patient
and family costs were of not sufficient magnitude to
influence the overall results.
To represent uncertainty around cost and effect data, a
joint distribution of these estimates was generated using
non-parametric bootstrapping [10]. The resulting boot-
strapped distributions of incremental cost and incremen-
Emergency 
department visits
Patient satisfaction 
survey
No. of visits National Hospital Data 
Collection - Public 
Section Estimated 
Round 9 (2004-05) - 
AR-DRG 5.0
Specialist referrals Medicare Australia 
data
No. of referrals MBS fee
Allied health visits Medicare Australia 
data
No. of referrals MBS fee when referred 
by a GP
Pharmaceutical costs Medicare Australia 
data
No. of prescriptions for 
conditions associated 
with the test
PBS dispensed price 
and copayment
Patient costs Motor vehicle travel Patient satisfaction 
survey
Distance (Km) Australian Taxation 
Office
Other travel costs (eg 
bus, taxi)
Patient satisfaction 
survey
Mean cost
Time seeking 
healthcare (travel time, 
waiting time)
Patient satisfaction 
survey
Time and motion study
Mean travel and 
waiting time
ABS seasonally 
adjusted average 
weekly earnings - 
applied whether were 
employed, 
unemployed or retired
* The effect of coning out of pathology was accounted for. Pathology providers can charge through the Medicare Benefits Schedule (MBS) 
fee only for the three most expensive tests ordered on the one occasion even when more tests are actually done. This is known as 'coning' 
and means that the tests recorded in the MBS data include only those charged for and not all that were done.
**87% of GP requested pathology is bulk-billed.
*** The high percentage of patients in the Trial who held health care cards or were pensioners (91%) and the location of practices in lower 
socio-economic status areas meant that most Medicare care items used in the Trial were bulked-billed so that patients did not make a 
copayment.
****Combined costs of items required to undertake each test. This included the testing strip/cassette, lancet, capillary tubes, plungers, urine 
pots, dipsticks and gloves. Periodically used items such as dust filters and cleaning kits were costed on an annual basis.
*****Hospitalisation rates were applied to a sample of patients obtained through the case note audit and weighted estimates generated for 
the Trial population to determine estimates for the whole sample. This approach was taken due to poor reporting of hospitalisations by 
practices. The hospitalisations were then assigned an AR-DRG code by a researcher blinded to the patient identification and their allocation 
to intervention or control under guidance from an expert AR-DRG coder. AR-DRG costs were adjusted by the CPI.
Table 2: Resource use items and unit costs for all tests (Continued)Laurence et al. BMC Health Services Research 2010, 10:165
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tal effectiveness were plotted, along with the actually-
observed base case.
Results
Cost comparisons
The point estimate of the total direct costs per patient to
the health care sector for PoCT was less for ACR than
pathology laboratory testing, but greater for INR, HbA1c
and lipids, although none of these differences was statisti-
cally significant. The cost comparisons for HbA1c which
illustrate the uncertainties involved are shown in Table 3,
and for the other tests in Additional File 1.
Some relatively large differences were found in the cost
components. Hospitalisation costs are reported below
because of their magnitude, but other costs only where
they were statistically significant. For HbA1c, PoCT
resulted in reduced costs for hospital admissions and sig-
nificantly increased costs for tests. For INR, PoCT
resulted in reduced costs for hospital admissions and sig-
nificantly reduced tests costs but significantly increased
consultation costs. ACR by PoCT resulted in reduced
costs for hospital admissions but significantly increased
test costs. Lipids by PoCT resulted in increased hospitali-
sation and significantly increased pharmaceutical costs.
For all tests, the intervention group had significantly
lower patient costs for travel and time seeking healthcare.
Incremental cost-effectiveness ratio point estimates
The effects per patient, the cost estimates and the point
estimates of the ICER for PoCT compared to laboratory
testing for each testing strategy are shown Table 4. ACR
testing at the point of care dominates testing through a
pathology laboratory, being both less costly and more
effective. Conversely, INR by PoCT was dominated by its
comparator (ie it was more expensive and less effective
than laboratory testing). The point estimates of the
ICERs for PoCT HbA1c and for Lipids fell in the north-
east quadrant of the incremental cost-effectiveness plane,
having higher costs and being more effective.
Sensitivity analyses
One-way sensitivity analyses of the incremental direct costs
The results of the one-way sensitivity analysis showed
that, for all tests, the incremental costs per patient were
most sensitive to differences in the costs of hospitalisa-
tion, and somewhat sensitive to differences in the costs of
GP consultations, pharmaceuticals and allied health visits
(see Additional Files 2).
One-way sensitivity analyses of the ICERs
The sensitivity of the base case ICER to changes in hospi-
talisations and GP consultations for each type of test is
shown in Table 5. These one-way sensitivity analyses
indicate that the ICER for each PoCT strategy is quite
sensitive to variation in hospitalisation costs. Variations
in GP costs have less influence, although the point esti-
mate of the ICER for HbA1c is shifted into a different
quadrant.
Joint probability distribution of the incremental costs and 
incremental effectiveness
The joint probability distribution of the incremental costs
and incremental effectiveness was modelled for each
PoCT strategy. The results are shown in Figure 1.
The joint probability distribution for INR is rather dif-
fuse, with all but a small proportion lying either within
the north-west (55.2%) or south-west (37.4%) quadrants
of the ICER plane. This suggests that the main problem
for this test is that it is less effective than a strategy based
on laboratory testing. For HbA1c, virtually all the joint
probability distribution lies within the north-east (36.4%)
or south-east (62.2%) quadrants. For ACR testing, 47.4%
of the bootstrapped results lie in the dominant quadrant
(south-east quadrant) and 27.6% of the distribution lies in
the north-west or south-west quadrants. For lipid testing,
the majority of the joint probability distribution lies in the
north-east quadrant (71.8%), indicating a trade-off
between greater effectiveness and higher cost. Because
the intermediate outcome indicator was specific to this
study and not readily comparable with other interven-
tions, it is unclear as to how much societal decision-mak-
ers would be willing to pay for maintaining an additional
patient in therapeutic range.
Discussion
This aspect of the Trial focused on evaluating the costs
per patient and the incremental cost-effectiveness of
implementing a PoCT strategy in GP compared to labora-
tory testing for INR, HbA1c, ACR and lipids within a
time horizon of 18 months. For all tests, there was no sta-
tistically significant difference in overall costs between
point of care and laboratory testing.
The study found a decrease in costs for hospital admis-
sions for PoCT for HbA1c, INR and ACR, although none
were statistically significant. This may have resulted from
improved management of patients when PoCT is used as
demonstrated in our Trial [9], which may in turn have
resulted in reduced hospital visits for patients with diabe-
tes or on anticoagulant therapy. In contrast, hospital
admission costs increased for the lipids PoCT group, but
again were not statistically significant. The sensitivity
analyses indicated that, across all tests, the costs of hospi-
tal admissions were the most uncertain. It is likely that
these results reflect the low power of the study to detect
differences in hospitalisation.
For HbA1c and ACR, the point estimates of the costs of
the PoC testing strategy were higher than in the control
group. This appeared to be largely due to the establish-
ment costs associated with introducing PoCT into a prac-
tice, the estimation of which required assumptions suchLaurence et al. BMC Health Services Research 2010, 10:165
http://www.biomedcentral.com/1472-6963/10/165
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as the useful clinical life and the relevant volume of test-
ing. The establishment costs included the cost of the
device, training, and quality assurance and represent a
key investment for the general practitioner, particularly
as a single general practice will never obtain the econo-
mies of scale and scope found in a pathology laboratory.
This element of the cost per patient would decrease if
patient volume increases.
Across the Trial, all PoC testing resulted in an increase
in the number of tests per person-year when compared to
the control group, but the greatest increase was found for
INR (12.0 tests per-person year compared with 9.3 tests
per person-year in the controls). Clinical guidelines rec-
ommend INR testing every 4-6 weeks [11], whereas test-
ing for HbA1c [12] and ACR [12,13] is recommended
every six months and 12 months respectively.
With PoCT , INR resulted in higher consultation costs
and this may relate to the higher number of GP visits per
person-year for the intervention group (19.2 visits per
person-year compared to 13.6 visits per person-year in
Table 3: Comparison of costs (direct and indirect) at 18 months for HbA1c tests - costs per patient (Australian dollars, 
calendar year 2006)
RESOURCES INTERVENTION (PoCT) N = 
1182
CONTROL (Laboratory) N 
= 785
DIFFERENCE (INTERVENTION - 
CONTROL)
Direct Costs to the health care 
sector
(95% CI) (95% CI) (95% CI)
Establishment costs in GP $114 $0* $114
Consumables & maintenance in 
GP
$28 ($22, $31) $0* $28 ($22, $31)
Quality assurance & control in GP $29 $0* $29
HbA1c tests (100% MBS fee in GP, 
85% MBS fee in pathology 
laboratory)
$64 ($49, $65) $98 ($88, $107) -$34 (-$54, -$28)
Sub total cost of actual test $235 ($184, $290) $98 ($88, $107) $137 ($84, $194)
GP consultations $579 ($515, $659) $560 ($502, $618) $18 (-$69, $112)
Hospital admissions $171 (-$181, $662) $506 (-$137, $1,241) -$334 (-$1,131, $460)
Emergency Dept visits $8 ($3, $13) $8 ($2, $13) -$1 (-$8, $7)
Specialist consultations $173 ($163, $183) $169 ($157, $180) $4 (-$11, $20)
Allied health visits $221 ($195, $253) $232 ($188, $282) -$11 (-$72, $47)
Pharmaceuticals $2,249 ($1,889, $2,555) $2,032 ($1,859, $2,586) $217 (-$280, $253)
Subtotal direct costs to 
healthcare sector
$3,636 ($3,019, $4,149) $3,606 ($2,902, $4,563) $30 (-$988, $673)
Direct Costs to the patients and 
families
Copayment for GP consultations 
and pharmaceuticals
$4 ($4, $6) $4 ($2, $6) $0 (-$2, $4)
Patient travel costs $12 ($10, $14) $28 ($23, $33) -$16 (-$22, -$11)
Subtotal direct costs to 
patients and families
$16 ($15, $19) $32 ($28, $39) -$16 (-$22, -$10)
Indirect Costs
Time seeking healthcare $23 ($22, $25) $34 ($32, $37) -$11 (-$14, -$8)
Total costs (both sectors)
Total $3,676 ($3,062, $4,191) $3,672 ($2,972, $4,628) $4 (-$1,103, $642)
Note: totals not exact due to rounding
* For the control group these items are included in the MBS fee for the laboratoryLaurence et al. BMC Health Services Research 2010, 10:165
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the control group). This in turn may result from the Trial
protocol, which required PoCT to be undertaken in con-
junction with a GP consultation.
With lipid testing, higher costs for pharmaceuticals
were found for the intervention group. This may again
relate to the better management of patients as shown by
Bubner et al [9], more regular testing (within the guide-
lines) and greater adherence to medications, resulting in
higher volumes of drugs being prescribed. The Trial
found the same or better adherence to medication for
hyperlipidaemia patients in the PoCT group compared
with the control group [14].
These incremental costs per patient were most sensi-
tive to differences in the costs of hospitalisation, and
somewhat sensitive to differences in the costs of GP con-
sultations, pharmaceuticals and allied health visits.
All four point of care tests led to significant savings for
patients and their families, (travel costs and copayments)
and, with the exception of INR, significant reductions in
time seeking healthcare. However, these costs were not of
sufficient magnitude to have much influence on the over-
all results (less than 5% of overall costs). To some extent
our results concur with other reports. Jowett et al [15], in
studying primary and secondary care anticoagulation
clinics in six countries, found that costs to the patients
were considerable, with the main driver being time costs.
Parry et al [16] found that travel time and time spent in
the clinic were significantly lower for patients attending
primary care clinics rather than secondary care clinics for
anticoagulant management. From a patient perspective,
PoCT can allow patients to have a pathology test and see
the GP about the results in one visit and thus can lead to
significant savings.
It is noteworthy that 91% of patients in the Trial held
health care cards or were pensioners, with the majority of
practices being located in lower socio-economic status
areas. This meant that most Medicare items used in the
Trial were bulk-billed so that patients did not make a co-
payment.
INR
The results of the base case analysis found INR to be both
less effective and more costly, and this was supported by
the sensitivity analyses. Most of the joint probability dis-
tribution for INR was in the north-west or south-west
quadrants. T his is str ong evidenc e t ha t t he INR P oCT
strategy implemented in the Trial was not cost-effective,
at least over the duration of follow-up in this study.
HbA1c
The results of the cost-effectiveness analysis for HbA1c
placed virtually all of the joint probability distribution
within the north-east (trade-off) or south-east (domi-
nant) quadrants. Although this result is somewhat
favourable, any recommendation to implement this test
at the point of care would depend on the value society
would place on maintaining a patient within the thera-
peutic range.
ACR
Although the point estimate of the ICER for ACR was in
the dominant quadrant, the joint probability distribution
was somewhat diffuse, extending into all four quadrants
Table 4: Point estimates of the incremental cost-effectiveness ratios (ICER) for PoC testing per patient maintained in the 
target range* compared with laboratory testing
Test Treatment Group Costs per patient ($) Effects per patient * ICER ($)
INR Intervention (PoCT) 3,298 0.5701
Control (Laboratory) 3,150 0.6147
Difference 148 -0.0446 Dominated
HbA1c Intervention (PoCT) 3,676 0.6548
Control (Laboratory) 3672 0.5618
Difference 4 0.0930 $40
ACR Intervention (PoCT) 1,727 0.7739
Control (Laboratory) 1,954 0.7418
Difference -228 0.0321 Dominant
Lipids Intervention (PoCT) 2,732 0.1592
Control (Laboratory) 2,202 0.1066
Difference 530 0.0526 $10,082
*Effect is the proportion of patients in target range as determined at the end of the Trial (18 months mean observation time)Laurence et al. BMC Health Services Research 2010, 10:165
http://www.biomedcentral.com/1472-6963/10/165
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and thus suggesting that before a positive policy recom-
mendation can be made, more precision in the estimate
of the ICER is required.
Lipids
For lipid testing, the point estimate of the ICER and most
of its joint distribution are within the north-east quad-
rant, indicating a trade-off between incremental costs
and incremental effectiveness. As the incremental effec-
tiveness is not expressed in life-years gained or QALYs, it
is uncertain whether the trade-off involved would be
acceptable to the policy maker. Thus, the implementation
of these tests using point of care would depend on the
value society would place on maintaining a patient within
the therapeutic range.
Comparing the results of the cost and the cost-effec-
tiveness analyses for this Trial with other studies is diffi-
cult because of the limited research in this area [16-22].
Those studies that do exist are also limited in their scope
and design. Only one study directly compared GP PoCT
with usual care using laboratory testing [21]. Moreover,
while some studies investigated cost-effectiveness,
[16,19,22] only one reported the incremental cost-effec-
tiveness ratio [19].
The Trial showed the point estimate of the INR PoCT
strategy to be dominated by laboratory testing. This con-
trasts with the results of a Belgian study which found the
use of a PoCT device for anticoagulant management
combined with a multifaceted education intervention was
dominant to usual care in GP [19]. Anticoagulant man-
agement in GP using PoCT, was also found to be more
costly by Parry et al [22]. This UK study investigated the
cost-effectiveness of PoCT, using data obtained through
an RCT of PoCT and computerised decision support to
manage anticoagulation therapy in GP. It found that the
costs per patient-year were significantly higher in pri-
Table 5: One-way sensitivity analysis on the ICERs (as expressed in dollars per patient maintained in target range)
Test Selected variables Cost per patient maintained in target range
INR Base ICER Dominated*
GP consultations - Upper 95% CI Dominated*
GP consultations - Lower 95% CI Dominated*
Hospital admissions - Upper 95% CI Dominated*
Hospital admissions - Lower 95% CI SW Quadrant**
HbA1c Base ICER $40
GP consultations - Upper 95% CI $1,049
GP consultations - Lower 95% CI Dominant***
Hospital admissions - Upper 95% CI $8,579
Hospital admissions - Lower 95% CI Dominant***
ACR Base ICER Dominant***
GP consultations - Upper 95% CI Dominant***
GP consultations - Lower 95% CI Dominant***
Hospital admissions - Upper 95% CI $17,647
Hospital admissions - Lower 95% CI Dominant***
Lipids Base ICER $10,082
GP consultations - Upper 95% CI $11,691
GP consultations - Lower 95% CI $8,618
Hospital admissions - Upper 95% CI $26,120
Hospital admissions - Lower 95% CI Dominant***
* Dominated: PoCT was more costly and less effective than laboratory testing
** SW Quadrant: PoCT was less costly and less effective than laboratory testing
***Dominant: PoCT was less costly and more effective than laboratory testing
Note: this analysis was undertaken on all the other variables (consumables, tests, emergency department visits, specialist consultations and 
pharmaceuticals) but did not have an influence on the ICERs ie change the quadrant.Laurence et al. BMC Health Services Research 2010, 10:165
http://www.biomedcentral.com/1472-6963/10/165
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mary care than in hospital-based clinics because of the
less efficient use of fixed costs. While sensitivity analysis
showed that costs to primary care could be reduced, they
still remained higher than secondary care. The cost driv-
ers were clinic sizes and the number of visits. The
reduced cost to patients and their families using PoCT for
anticoagulant management in this study confirmed a pre-
vious finding by Parry et al [16]. In contrast, another
study which investigated HbA1c PoCT in a GP setting
found no differences in patient-borne costs between the
intervention and control group (laboratory testing) [21].
The results for HbA1c from this Trial are congruent
with work undertaken in the United Kingdom by Khunti
et al [21]. This small study assessed the effect and cost of
using PoCT for HbA1c testing in the management of
Type 2 diabetes in GP. They found no difference in the
total cost for diabetes care using PoCT compared with
laboratory testing.
There are no previous studies about the comparative
costs and cost-effectiveness of PoCT for ACR or lipids in
a GP setting.
Limitations
This cost-effectiveness analysis had a number of limita-
tions. Firstly, the Trial used an intermediate outcome
indicator in the ICER. This indicator is specific to this
Trial and not immediately generalisable, unlike life-years
gained or QALYs, thus making the interpretation of the
acceptability of the trade-offs difficult. Additionally, the
short duration of the Trial may have limited the identifi-
cation of any clear health gains, which in turn would
influence the ICER.
Secondly, limitations arose from using Medicare data to
estimate costs and volumes. Medicare data were used to
determine the volume of tests used in the costing analy-
sis, because analysis of the data provided directly from
the practices and Pathology Providers indicated under-
reporting of results, particularly for the control group.
However, with Medicare data, the number of tests
claimed is not identifiable by type of medical practitioner,
and so some tests included in the analysis may have been
ordered for that patient by a specialist and not a general
practitioner.
Thirdly, the wide ranges of the CIs suggest that the
Trial may have been underpowered for measuring costs.
The power calculation for the Trial was based on the pri-
mary outcome of the proportion of patients with test
results within the target range. Fourthly, Pharmaceutical
Benefits Scheme (PBS) data provides incomplete drug
utilisation history, as only scripts priced over the copay-
Figure 1 Joint probability distribution of the incremental costs and effects of PoCT for INR, HbA1c, ACR and Lipids.Laurence et al. BMC Health Services Research 2010, 10:165
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ment threshold are recorded. However, as the PBS was
used for both arms of the Trial, this limitation would
apply to both groups.
Finally, the PoCT Trial was not able to recruit sufficient
patients in two of the three conditions to obtain the
desired power of 80%, which may limit the interpretation
of the results.
Conclusions
The results add to the small body of work on the eco-
nomic value of PoCT. To obtain the maximum available
health benefits from scarce clinical resources, it is impor-
tant that new health technologies be assessed for their
cost-effectiveness. Health care funders are increasingly
relying on information to assist them in maintaining
value for money. This should also minimise waste of
these resources. In this Trial, the cost-effectiveness for
PoCT with ACR was found to be somewhat favourable,
thereby providing evidence to support its implementa-
tion in GP in Australia. On the other hand, INR by PoCT
was not cost-effective and its introduction into routine
GP is not supported by this study. This suggests that fur-
ther research into the technology itself might be worth
pursing or into a better regime of testing. Moreover, sub-
stantial uncertainty still surrounds PoCT for HbA1c and
Lipids, suggesting more development work before PoCT
can be introduced into GP.
Cost-effectiveness analysis is merely one useful tool for
the decision-maker. While the results of this study pro-
vide valuable information about the effectiveness and
costs for PoCT in GP, other factors need to be considered
when determining whether this strategy should be imple-
mented nation-wide [23]. These include GP, device oper-
ator and patient satisfaction with PoCT, its impact on GP
management and improved adherence to medications by
intervention patients. The PoCT Trial has demonstrated
that: patients are satisfied with PoCT and find it accept-
able [24]; that PoCT provides an effective alternative to
pathology laboratory testing and can enhance GP man-
agement of patients with chronic disease [9]; and that
PoCT can assist patients in self-management behaviours
such as medication adherence [14]. The costs associated
with introducing PoCT within a quality framework were
high for the Trial and involved accreditation, a quality
assurance program and training. While a quality frame-
work is essential for the introduction of PoCT in GP , it
may be possible to achieve the same quality outcomes at a
reduced cost by adding these to existing organisations or
programs or by using alternatives such as online training.
These factors may influence the decision to support
PoCT.
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